Neuronetics Showcases NeuroStar TMS Data at Clinical TMS Meeting

Neuronetics Inc. (NASDAQ:STIM) is one of the best-performing NASDAQ stocks according to analysts. On June 10, Neuronetics announced its significant presence at the 13th Annual Clinical TMS Society/CTMSS Meeting and provided an update on Greenbrook’s Personalized Care Trial Program. NeuroStar, which is Neuronetics’ brand, participated as a Silver Sponsor at the CTMSS Meeting, which took place from June 11 to June 14 this year in San Diego, CA.

The company showcased its commitment to clinical innovation by presenting two posters derived from the TrakStar data set, which is the largest real-world outcomes database in Transcranial Magnetic Stimulation/TMS. During the CTMSS Meeting, NeuroStar presented two key data sets. One presentation focused on the largest-to-date analysis of elderly adults (age 70 and older) with Major Depressive Disorder/MDD treated with TMS. The other one provided a retrospective analysis of data from 200 Greenbrook centers, offering a direct comparison of clinical outcomes between NeuroStar’s proprietary Figure-8 coil and Brainsway’s H-coil in the treatment of depression.

Neuronetics Showcases NeuroStar TMS Data at Clinical TMS Meeting

A lab technician gazing into a microscope, analyzing sample slides for medical technology research.

NeuroStar also participated in the PULSES Course, a foundational training session for TMS providers, and exhibited at booth #303. Additionally, Neuronetics provided an update on Greenbrook Mental Wellness Centers’ Personalized Care Trial Program. Greenbrook is a wholly-owned subsidiary of Neuronetics and initiated this program to assess the feasibility of using personalized qEEG-informed protocols for delivering TMS therapy with the NeuroStar TMS System.

Neuronetics Inc. (NASDAQ:STIM) provides office treatments for patients with neurohealth disorders in the US and internationally.

While we acknowledge the potential of STIM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than STIM and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.